Brief: Crispr Therapeutics Reports Positive Additional Phase 1 Data For Ctx310™ Targeting Angptl3 And Provides Update On In Vivo Cardiovascular Pipeline

Crispr Therapeutics AG

26/06/2025 12:04

June 26 (Reuters) - CRISPR Therapeutics AG CRSP.BN:

CRISPR THERAPEUTICS REPORTS POSITIVE ADDITIONAL PHASE 1 DATA FOR CTX310™ TARGETING ANGPTL3 AND PROVIDES UPDATE ON IN VIVO CARDIOVASCULAR PIPELINE

CRISPR THERAPEUTICS AG - CTX310 SHOWS UP TO 82% TG AND 86% LDL REDUCTION

CRISPR THERAPEUTICS AG - CTX320 DATA UPDATE EXPECTED IN H1 2026

CRISPR THERAPEUTICS AG - COMPLETE PHASE 1 DATA FOR CTX310 EXPECTED IN H2 2025

Source text: ID:nGNX5K2k2m

Further company coverage: CRSP.BN

 ((Reuters.Briefs@thomsonreuters.com;))